Overview

Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Status:
Completed
Trial end date:
2017-12-13
Target enrollment:
Participant gender:
Summary
Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Shire